"Can't Ignore": Karti Chidambaram As Over 3 Lakh Dog Bites Reported In 2024
"We can't ignore this any more! #Streetdogs," the Lok Sabha MP from Tamil Nadu's Sivaganga constituency said in a post on X.
In a written reply in the Lower House, Minister of State for Fisheries, Animal Husbandry and Dairying S P Singh Baghel said the total dog bite cases in 2024 stood at 37,17,336 while the total 'suspected human rabies deaths' were 54.
The minister said the data is collected from states/Union Territories under the National Rabies Control Program by the National Centre for Disease Control (NCDC).
We can't ignore this any more! #Streetdogs pic.twitter.com/6sT4z4DcmO
— Karti P Chidambaram (@KartiPC) July 22, 2025
"The Department provides financial support under the Assistance to State for Control of Animal Diseases component of the Livestock Health and Disease Control Programme for procurement of anti-rabies vaccines for animals, including stray dogs," the written reply said.
Rabies remains a significant public health challenge in India, accounting for 36% of global rabies deaths and causing an estimated 18,000 to 20,000 fatalities annually, with a disproportionate impact on children under 15. Despite these alarming statistics, rabies deaths are entirely preventable with prompt and complete post-exposure prophylaxis.
The Centre is aiming to eliminate rabies by 2030.
In the past six months, Karnataka has recorded more than 2.3 lakh dog bite cases and 19 rabies deaths, indicating a sharp increase compared to the corresponding period last year, according to official data released on Sunday. In all of 2024, the state reported 3.6 lakh dog bite cases and 42 rabies deaths.
The Bruhat Bengaluru Mahanagara Palike (BBMP) - Bengaluru's civic body - shared details of its Rs 2.88 crore plan to feed about 4,000 street dogs in the city and said it has invited a tender in this regard after reviewing the pros and cons of the initiative. Feeding makes it easier to catch the dogs for sterilisation and vaccination. This, in turn, boosts the effectiveness of animal birth control and anti-rabies vaccination campaigns, the civic body said.
Kerala is planning to launch a crackdown on stray dogs by rolling out mobile sterilisation units in 152 blocks and permitting the euthanasia of seriously ill animals, Local Self-Government Minister M B Rajesh said last week.
Since April this year, four children from various parts of the state have died after being bitten by stray dogs, despite receiving the anti-rabies vaccine.
According to Mr Rajesh, 158 trained personnel from the Animal Husbandry Department are currently available for catching stray dogs.
The Kerala Health and Education departments are together planning to organise an awareness programme against rabies in government and aided schools in the state from June 30.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
3 hours ago
- Time of India
Body of Kodagu man being brought back from Guyana
Madikeri: Mortal remains of a resident of Kodagu, who died in Guyana, will be brought back to India, the Non-Resident Indian Forum said on Wednesday. The state govt will extend financial assistance to bring back the body of PB Girish Babu Pale, who is a native of Madenadu village in Madikeri taluk, it stated. Girish was working as a staff nurse in the Sheriff General Hospital in Guyana, South America, for about two years. On July 3, he was admitted to the hospital where he was working due to illness and was undergoing treatment. However, he died of a heart attack on July 14. Following the incident, the family was in constant touch with the hospital and the Indian Embassy to bring the mortal remains to India. The embassy informed that the family of the deceased would have to pay about Rs 12 lakhs to bring the mortal remains to India. Janaki, wife of Girish, appealed to the Non-Resident Indian Forum for assistance from the govt, stating that the family was financially backward. Accordingly, the forum requested chief minister Siddaramaiah to consider the request. Janaki also met the CM and sought his intervention. In response, the state govt sanctioned Rs 3.6 lakh while the remaining amount is being borne by the Sheriff General Hospital where Girish worked, the Forum stated on Wednesday. In addition, the alumni of Basavanahalli Morarji Desai Residential School, where Girish studied, approached Virajpet MLA AS Ponnanna and requested him to provide financial assistance. The Indian Embassy in Guyana and the resident commissioner in New Delhi are coordinating the bringing of the body to India.
Economic Times
4 hours ago
- Economic Times
Potential US tariff a significant 'unknown' for business, says Dr Reddy's Lab CEO
Dr. Reddy's Laboratories is closely monitoring a potential US tariff on the pharma sector, viewing it as both a risk and opportunity. The company plans a significant expansion with the generic version of semaglutide across 87 countries by 2026, alongside developing 26 GLP-1 products over the next decade. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads A potential US tariff on the pharma sector is a significant 'unknown' and will be one of the key developments for Dr Reddy's Laboratories to watch over the next few quarters, its chief executive officer, Erez Israeli , told ET.'Don't know whether to call it a risk, but it is an unknown that could develop into a risk, and that is the tariff. We will know better as time will come about what it means and what we can do,' Israeli said over an earning call on Wednesday. 'It's not necessarily bad, it can also create an opportunity. It very much depends on what will be our relative situation to Chinese players or others.'The Hyderabad-based drug maker, which announced its first-quarter earnings, is betting big on generic version of Novo Nordisk 's weight loss molecule semaglutide – that it plans to launch in 87 countries in 2026 - as a future growth driver.'Our levers for the future consist of double-digit growth of the main business and then on top of it the success of semaglutide, which is very important to us, business development and our ability to optimise our resources,' Israeli said in response to ET's query.'We are planning to launch semaglutide in 87 countries as the patent in the relevant country will allow us… We have some countries where there is no active patent as we speak, and in those we can launch. In the other countries, we need to wait for the patent expiration - for example Brazil or India - in which the patent goes on till March 2026. We are absolutely ready to launch on day 1 (post patent expiry) in each one of these markets,' he company which is among the frontrunners for GLP-1 drugs is looking at launching 26 other products in the space over the next decade.'We have 26 products (all peptides) in the GLP1 pipeline and will be launched over the next decade, according to the patent situation,' said Wednesday, the company reported consolidated revenue for the first quarter at Rs 8,545 crore, an 11% increase from a year ago, mainly on account of contributions from its acquired consumer healthcare portfolio in nicotine replacement therapy (NRT) and sustained performance in branded markets. Net profit for the quarter stood at Rs 1,418 crore, up 2% said an ongoing litigation over semaglutide with innovator company Novo Nordisk in India is not likely to hamper its planned product company's global generics revenue in Q1FY26 stood at Rs 7,562 crore, a growth of 10% revenue from North America–one of its key markets–declined 11% y-o-y to Rs 3,412 crore due to increased price erosion in select products, including lenalidomide. Its Europe revenue stood at Rs 1,274 crore, up 142% on account of NRT portfolio company's India and emerging markets business grew 11% and 17% company's EBITDA margin for the first quarter stood at 26.7%.
Time of India
4 hours ago
- Time of India
Potential US tariff a significant 'unknown' for business, says Dr Reddy's Lab CEO
A potential US tariff on the pharma sector is a significant 'unknown' and will be one of the key developments for Dr Reddy's Laboratories to watch over the next few quarters, its chief executive officer, Erez Israeli , told ET. 'Don't know whether to call it a risk, but it is an unknown that could develop into a risk, and that is the tariff. We will know better as time will come about what it means and what we can do,' Israeli said over an earning call on Wednesday. 'It's not necessarily bad, it can also create an opportunity. It very much depends on what will be our relative situation to Chinese players or others.' Explore courses from Top Institutes in Please select course: Select a Course Category Technology Leadership Project Management Healthcare Management Data Analytics Data Science others Cybersecurity Artificial Intelligence Design Thinking Degree Product Management Public Policy Data Science MCA Finance MBA Others healthcare Operations Management PGDM CXO Digital Marketing Skills you'll gain: Duration: 12 Weeks MIT xPRO CERT-MIT XPRO Building AI Prod India Starts on undefined Get Details The Hyderabad-based drug maker, which announced its first-quarter earnings, is betting big on generic version of Novo Nordisk 's weight loss molecule semaglutide – that it plans to launch in 87 countries in 2026 - as a future growth driver. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like No annual fees for life UnionBank Credit Card Apply Now Undo 'Our levers for the future consist of double-digit growth of the main business and then on top of it the success of semaglutide, which is very important to us, business development and our ability to optimise our resources,' Israeli said in response to ET's query. 'We are planning to launch semaglutide in 87 countries as the patent in the relevant country will allow us… We have some countries where there is no active patent as we speak, and in those we can launch. In the other countries, we need to wait for the patent expiration - for example Brazil or India - in which the patent goes on till March 2026. We are absolutely ready to launch on day 1 (post patent expiry) in each one of these markets,' he said. Live Events The company which is among the frontrunners for GLP-1 drugs is looking at launching 26 other products in the space over the next decade. 'We have 26 products (all peptides) in the GLP1 pipeline and will be launched over the next decade, according to the patent situation,' said Israeli. On Wednesday, the company reported consolidated revenue for the first quarter at Rs 8,545 crore, an 11% increase from a year ago, mainly on account of contributions from its acquired consumer healthcare portfolio in nicotine replacement therapy (NRT) and sustained performance in branded markets. Net profit for the quarter stood at Rs 1,418 crore, up 2% y-o-y. Israeli said an ongoing litigation over semaglutide with innovator company Novo Nordisk in India is not likely to hamper its planned product launches. The company's global generics revenue in Q1FY26 stood at Rs 7,562 crore, a growth of 10% year-on-year. However, revenue from North America–one of its key markets–declined 11% y-o-y to Rs 3,412 crore due to increased price erosion in select products, including lenalidomide. Its Europe revenue stood at Rs 1,274 crore, up 142% on account of NRT portfolio acquisition. The company's India and emerging markets business grew 11% and 17% respectively. The company's EBITDA margin for the first quarter stood at 26.7%.
